- Low
- 42,000
- Average
- 42,000
- Median
- 42,000
- High
- 42,000
Phaserx Salary
80
60
56
Phaserx average salary is $42,000, median salary is $42,000 with a salary range from $42,000 to $42,000.
Phaserx salaries are collected from government agencies and companies. Each salary is associated with a real job position. Phaserx salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Phaserx salaries are collected from government agencies and companies. Each salary is associated with a real job position. Phaserx salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
| Job Title | Salaries | City | Year | More info |
Calculate how much you could earn
It's FREE. Based on your input and our analysis. How we do it?
All fields are required for calculation accuracy.
- We will send you an email to access your personalized report.
- We won’t share your email address
Phaserx salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.
Real Jobs Salary - Salary List- 8.5 million company & government reported salaries with date & location
- Salary calculator rank & calculate your salary
- 151 million W-2s pay scale statistics in U.S.
- Salary Map helps you navigate location based salary information
- State & City Salary provides wage data by metropolitan areas
- Company Salaries has salaries data from over 200,000 companies
Phaserx Jobs
| See more Phaserx Jobs» | |
| Search All Jobs | |
Patents information
165
All Patents
41
Grant Patents
116
Patents Pending
24
Patents Families
More Recent
Phaserx... Information
- PhaseRx, Inc
- Industry: Drugs
- City: Seattle, WA
- PhaseRx is an RNAi delivery technology company developing a breakthrough polymer-based system that enables the systemic delivery of RNAi-based drugs and potentially other macromolecules as therapeutic products. Development of RNAi therapeutics, a new class of pharmaceuticals with significant market potential, has been hindered to date by the lack of effective delivery technology. PhaseRx was founded to solve a critical challenge in RNAi delivery: the need for a versatile, developable system that can be administered systemically and deliver RNAi drugs into the cell where they can reach and inhibit the drug targets.
